ContraFect Corporation Stock News

ContraFect (NASDAQ:CFRX) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of t

YONKERS, N.Y., March 30, 2020 -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents.

Maxim Group reiterated their buy rating on shares of ContraFect (NASDAQ:CFRX) in a research note published on Thursday morning, AnalystRatings.com reports. The firm currently has a $22.00 target price

By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update Update on Phase 3 DISRUPT Trial In January, 2020, ContraFect Corp. (NASDAQ:CFRX) announced the first patient had been

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

YONKERS, N.Y., March 18, 2020 -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents.

ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modal

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ContraFect (CFRX) and United Therapeutics (UTHR).

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ContraFect ( CFRX – Research Report ) and United Therapeutics ( UTHR – Research Report ). ContraFec

NGM Biopharmaceuticals (NASDAQ:NGM) +67% after aldafermin phase 2 results.NanoViricides (NYSEMKT:NNVC) +39% on drugmakers working on coronavirus.Enlivex Therapeutics (NASDAQ:ENLV) +37% after disclo

ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modal

By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Financial Update On February 4, 2020, ContraFect (NASDAQ:CFRX) announced a one-for-ten reverse stock split. We have updated this repo

NEW YORK (AP) — Changes announced in corporate dividends Feb. 3-Fev. 7. INCREASED DIVIDENDS Activision Blizzard .41 from .37 Aflac Inc .28 from .27 Arch Coal Inc Cl A .50 from .45 Avista Corp .405 f

ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modal

ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modal